Answer
Imbruvica (ibrutinib) is not recommended for children and adolescents aged 0 to 18 years because efficacy has not been established.
Sources for this answer
- IMBRUVICA 140 mg film-coated tablets (Great Britain)Janssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.2 Posology and method of administration · Version 25Document updated
Sources checked